Latest court orders, judgments, and legal developments from Indian courts — AI-curated and summarized.
FeaturedThe Delhi High Court upheld the rejection of a pharmaceutical patent due to lack of inventive step, despite acknowledging novelty. The ruling clarifies the hierarchy of patentability criteria under Indian law.
FeaturedThe Kerala High Court interpreted Section 100 of the Patents Act, allowing government use of patented inventions for public health. The ruling balances access to medicine with patent rights, emphasizing statutory safeguards.
FeaturedThe Kerala High Court upheld government use of Novartis's patented cancer drug Ribociclib under Section 100 of the Patents Act for public health purposes, prioritizing access over patent exclusivity in emergencies. The decision balances TRIPS flexibilities with domestic public interest.
FeaturedDelhi High Court in Esteve Pharmaceuticals v. Controller clarified that novelty and inventive step must be assessed separately in patent rejection appeals. The case upheld lack of inventive step despite acknowledging novelty.
FeaturedThe Kerala High Court addressed government use of a patented cancer drug, Ribociclib, under Section 100 of the Patents Act, balancing access to medicine against patent rights. The ruling underscores tensions between public health policy and IP enforcement.
FeaturedThe Kerala High Court interpreted Section 100 of the Patents Act in a government use case involving the drug Ribociclib, balancing access to medicine with patent rights. The decision underscores tensions between public health policy, drug pricing, and patent enforcement.
FeaturedA Kerala High Court judgment on government use of patented invention under Section 100 of the Patents Act, 1970 reignites debate on access to medicine, pricing, and policy balance in the context of the drug Ribociclib.
FeaturedThe Kerala High Court addressed the scope of Section 100 of the Patents Act, 1970, in the context of access to the cancer drug ribociclib. The ruling balances public health interests against patent rights, emphasizing lawful government use for public welfare.
FeaturedThe Kerala High Court ruled on government use of a patented cancer drug Ribociclib under Section 100 of the Patents Act, balancing access to medicine against patent rights amid evolving drug pricing and enforcement policies.
FeaturedThe Kerala High Court ruled on government use of patented inventions under Section 100 of the Patents Act in the context of access to Ribociclib, a cancer drug. The order balances public health needs with patent rights, amid evolving pricing and enforcement policies.
FeaturedThe Kerala High Court interpreted Section 100 of the Patents Act, 1970, permitting government use of a patented invention for public health, raising critical questions on access to medicine, patent rights, and pricing policy.
FeaturedThe Kerala High Court interpreted Section 100 of the Patents Act, allowing government use of a patented cancer drug, Ribociclib, in public health emergencies. The ruling balances patent rights with access to medicine, citing compulsory licensing and public interest.